Getagraph.com logo
NASDAQ Composite: ( -0.07%) 16 686
S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(0.97%) $80.00
Gas
(5.73%) $2.64
Gold
(1.44%) $2 419.80
Silver
(6.36%) $31.78
Platinum
(2.18%) $1 094.70
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.18%) $10.68
USD/GBP
(-0.27%) $0.787
USD/RUB
(0.19%) $91.05

リアルタイムの更新： Leap Therapeutics Inc [LPTX]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-05-20)

Expected move: +/- 14.57%

BUY
100.00%
return 10.47%
SELL
0.00%
return 11.12%
最終更新日時18 5月 2024 @ 05:00
25% discount on Stockinvest.us - Use code: Podcast

-4.01% $ 2.63

売る 145292 min ago

@ $3.52

発行日: 9 2月 2024 @ 04:59

リターン: -25.28%

前回のシグナル: 2月 8 - 05:44

前回のシグナル: 買う

リターン: 2.03 %

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers...

Stats
本日の出来高 375 785
平均出来高 307 798
時価総額 100.64M
EPS $0 ( 2024-05-13 )
次の収益日 ( $-0.570 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.660
ATR14 $0.0230 (0.87%)
Insider Trading
Date Person Action Amount type
2024-04-10 Gilead Sciences, Inc. Sell 0 Common Stock
2024-01-29 Mashiach Nissim Buy 25 000 Stock Option (Right to Buy)
2024-01-29 Dietz Thomas John Buy 30 000 Stock Option (Right to Buy)
2024-01-29 Schilsky Richard Buy 25 000 Stock Option (Right to Buy)
2024-01-29 Granfield Christine Buy 85 000 Employee Stock Option (Right to Buy)
INSIDER POWER
66.43
Last 95 transactions
Buy: 10 825 606 | Sell: 1 768 106

ボリューム 相関

長: 0.14 (neutral)
短: -0.76 (moderate negative)
Signal:(53.092) Neutral

Leap Therapeutics Inc 相関

10 最も正の相関
10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Leap Therapeutics Inc 相関 - 通貨/商品

The country flag 0.52
( weak )
The country flag 0.44
( neutral )
The country flag 0.00
( neutral )
The country flag 0.61
( weak )
The country flag 0.29
( neutral )
The country flag 0.47
( neutral )

Leap Therapeutics Inc 財務諸表

Annual 2023
収益: $0
総利益: $-427 000 (0.00 %)
EPS: $-3.98
FY 2023
収益: $0
総利益: $-427 000 (0.00 %)
EPS: $-3.98
FY 2022
収益: $0
総利益: $-415 000 (0.00 %)
EPS: $-4.82
FY 2021
収益: $1.50M
総利益: $1.50M (100.00 %)
EPS: $-0.470

Financial Reports:

No articles found.

Leap Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。